{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:43:32Z","timestamp":1783446212019,"version":"3.55.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.exer.2018.11.022","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T19:10:02Z","timestamp":1542913802000},"page":"43-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders"],"prefix":"10.1016","volume":"180","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4894-2745","authenticated-orcid":false,"given":"Tjing-Tjing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vanhove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3125-0438","authenticated-orcid":false,"given":"Inge","family":"Van Hove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Van Bergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2762-8522","authenticated-orcid":false,"given":"Bart","family":"Jonckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Barbeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Vermassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean H.M.","family":"Feyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2018.11.022_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1442-9071.2010.02194.x","article-title":"Expression of advanced glycation end products and related molecules in diabetic fibrovascular epiretinal membranes","author":"Abu El-Asrar","year":"2010","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2018.11.022_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/jpet.118.248427","article-title":"Ocular distribution and pharmacodynamics of SF0166, a topically administered alphavbeta3 integrin antagonist, for the treatment of retinal diseases","author":"Askew","year":"2018","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.exer.2018.11.022_bib3","doi-asserted-by":"crossref","first-page":"46707","DOI":"10.1074\/jbc.M106176200","article-title":"Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity","author":"Bhowmick","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.exer.2018.11.022_bib4","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2214-109X(13)70113-X","article-title":"Causes of vision loss worldwide, 1990-2010: a systematic analysis","volume":"1","author":"Bourne","year":"2013","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.exer.2018.11.022_bib5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.exer.2018.11.022_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4161\/cam.20252","article-title":"Pericyte-endothelial cell interaction: a survival mechanism for the tumor vasculature","author":"Chatterjee","year":"2012","journal-title":"Cell Adhes. Migrat."},{"key":"10.1016\/j.exer.2018.11.022_bib7","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/eye.2009.108","article-title":"Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis?","volume":"23","author":"Curtis","year":"2009","journal-title":"Eye"},{"key":"10.1016\/j.exer.2018.11.022_bib8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of scar in the comparison of age-related macular degeneration treatments trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.11.022_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.exer.2015.05.003","article-title":"Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data","author":"Del Amo","year":"2015","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.11.022_bib1a","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.ophtha.2011.02.018","article-title":"The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema","volume":"118","author":"Do","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.11.022_bib11","first-page":"1029","article-title":"Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis","author":"Dvorak","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2018.11.022_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/CS20160129","article-title":"Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems","author":"Eklund","year":"2017","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.exer.2018.11.022_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1083\/jcb.200109079","article-title":"Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling","author":"Eliceiri","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.exer.2018.11.022_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-002269","article-title":"Current treatments in diabetic macular oedema: systematic review and meta-analysis","volume":"3","author":"Ford","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.exer.2018.11.022_bib15","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1126\/science.270.5241.1500","article-title":"Definition of two angiogenic pathways by distinct alpha v integrins","author":"Friedlander","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.exer.2018.11.022_bib16","doi-asserted-by":"crossref","first-page":"9764","DOI":"10.1073\/pnas.93.18.9764","article-title":"Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases","author":"Friedlander","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.exer.2018.11.022_bib17","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1167\/iovs.07-0469","article-title":"Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761","author":"Fu","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.11.022_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1089\/jop.2016.0083","article-title":"Binding to ocular albumin as a half-life extension principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies","author":"Fuchs","year":"2017","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.exer.2018.11.022_bib19","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1021\/pr800112g","article-title":"Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy","volume":"7","author":"Gao","year":"2008","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.exer.2018.11.022_bib20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/gut.2005.079178","article-title":"A novel integrin alpha5beta1 binding domain in module 4 of connective tissue growth factor (CCN2\/CTGF) promotes adhesion and migration of activated pancreatic stellate cells","author":"Gao","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.exer.2018.11.022_bib21","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1096\/fj.06-6390com","article-title":"VLA-4 blockade suppresses endotoxin-induced uveitis: in vivo evidence for functional integrin up-regulation","author":"Hafezi-Moghadam","year":"2007","journal-title":"Faseb. J."},{"key":"10.1016\/j.exer.2018.11.022_bib22","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1038\/ncomms6962","article-title":"Endothelial destabilization by angiopoietin-2 via integrin beta1 activation","author":"Hakanpaa","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.exer.2018.11.022_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nm0596-529","article-title":"Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization","author":"Hammes","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.exer.2018.11.022_bib24","doi-asserted-by":"crossref","first-page":"7373","DOI":"10.1074\/jbc.M115.710186","article-title":"Angiopoietin-like protein 2 is a multistep regulator of inflammatory neovascularization in a murine model of age-related macular degeneration","author":"Hirasawa","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2018.11.022_bib25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1001\/archopht.123.4.509","article-title":"Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey","author":"Husain","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2018.11.022_bib26","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1167\/iovs.08-2013","article-title":"Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy","author":"Iliaki","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.11.022_bib27","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2353\/ajpath.2007.061018","article-title":"Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization","author":"Izumi-Nagai","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.exer.2018.11.022_bib28","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1074\/mcp.M115.053249","article-title":"Quantitative proteomics reveals beta2 integrin-mediated cytoskeletal rearrangement in vascular endothelial growth factor (VEGF)-induced retinal vascular hyperpermeability","author":"Jo","year":"2016","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.exer.2018.11.022_bib29","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1096\/fj.03-1476fje","article-title":"A central role for inflammation in the pathogenesis of diabetic retinopathy","author":"Joussen","year":"2004","journal-title":"Faseb. J."},{"key":"10.1016\/j.exer.2018.11.022_bib30","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/labinvest.2012.111","article-title":"Angiopoietin-like protein 2 mediates endotoxin-induced acute inflammation in the eye","author":"Kanda","year":"2012","journal-title":"Lab. Invest."},{"key":"10.1016\/j.exer.2018.11.022_bib31","unstructured":"Karageozian,H.L., Park,J.Y., and Karageozian,V.H. (2018). Therapeutic and neuroprotective peptides. US patent application publication US 2018\/0207227 A1."},{"issue":"Suppl. 2","key":"10.1016\/j.exer.2018.11.022_bib32","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar2187","article-title":"Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis","volume":"9","author":"Koch","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.exer.2018.11.022_bib33","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.exer.2018.11.022_bib34","doi-asserted-by":"crossref","first-page":"8665","DOI":"10.1167\/iovs.10-6768","article-title":"Beyond AREDS: is there a place for antioxidant therapy in the prevention\/treatment of eye disease?","volume":"52","author":"Kowluru","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.11.022_bib2a","first-page":"85","article-title":"A dual-mechanism drug for vitreoretinal diseases","author":"Kuppermann","year":"2015","journal-title":"Retina Today"},{"key":"10.1016\/j.exer.2018.11.022_bib3a","article-title":"Topline Results from prospective, double-masked, placebo controlled phase 2 clinical study evaluating luminate\u00ae (ALG-1001) in patients with symptomatic focal vitreomacular adhesion","author":"Kuppermann","year":"2016","journal-title":"ARVO"},{"key":"10.1016\/j.exer.2018.11.022_bib35","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1096\/fj.07-8273com","article-title":"Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease","author":"Lahdenranta","year":"2007","journal-title":"Faseb. J."},{"key":"10.1016\/j.exer.2018.11.022_bib36","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1186\/1755-1536-5-S1-S24","article-title":"CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis","author":"Lipson","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.exer.2018.11.022_bib37","doi-asserted-by":"crossref","first-page":"20991","DOI":"10.1074\/jbc.M111.226266","article-title":"Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization","author":"Liu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exer.2018.11.022_bib38","unstructured":"Mackel,M.J., Park,J.Y., Karageozian,H.L., and Karageozian,V.H. (2013). Integrin receptor antagonists and their methods of use. US patent application publication US 2013\/0129621 A1."},{"key":"10.1016\/j.exer.2018.11.022_bib39","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/CIRCRESAHA.107.155655","article-title":"Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis","author":"Mahabeleshwar","year":"2007","journal-title":"Circ. Res."},{"key":"10.1016\/j.exer.2018.11.022_bib40","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V95.5.1560.005k43_1560_1564","article-title":"Association between diabetic retinopathy and genetic variations in alpha2beta1 integrin, a platelet receptor for collagen","author":"Matsubara","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exer.2018.11.022_bib41","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.11.022_bib42","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.298.8.902","article-title":"Management of diabetic retinopathy: a systematic review","volume":"298","author":"Mohamed","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.exer.2018.11.022_bib43","article-title":"Vascular hyperpermeability, angiogenesis, and stroma generation","volume":"4","author":"Nagy","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.exer.2018.11.022_bib44","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.11.022_bib45","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2010.08.016","article-title":"Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study","author":"Nguyen","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.11.022_bib46","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3129\/i08-145","article-title":"Expression of integrins in human proliferative diabetic retinopathy membranes","author":"Ning","year":"2008","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.exer.2018.11.022_bib47","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.2337\/db13-1942","article-title":"Angiopoietin 2 induces pericyte apoptosis via alpha3beta1 integrin signaling in diabetic retinopathy","author":"Park","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.exer.2018.11.022_bib48","first-page":"273","article-title":"Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent","volume":"5","author":"Ramakrishnan","year":"2006","journal-title":"J. Exp. Therapeut. Oncol."},{"key":"10.1016\/j.exer.2018.11.022_bib49","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1167\/iovs.09-5144","article-title":"Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR)","author":"Rao","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.11.022_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exer.2013.04.014","article-title":"A novel ex vivo murine retina angiogenesis (EMRA) assay","author":"Rezzola","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.11.022_bib51","first-page":"3475","article-title":"Immunolocalization of integrins in proliferative retinal membranes","author":"Robbins","year":"1994","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.11.022_bib52","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-Year outcomes in ranibizumab-treated patients in anchor, marina, and horizon: a multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2018.11.022_bib53","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev.cellbio.12.1.697","article-title":"RGD and other recognition sequences for integrins","volume":"12","author":"Ruoslahti","year":"1996","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.exer.2018.11.022_bib54","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1124\/jpet.107.131656","article-title":"Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats","volume":"324","author":"Santulli","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"7","key":"10.1016\/j.exer.2018.11.022_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069552","article-title":"Choroid sprouting assay: an ex vivo model of microvascular angiogenesis","volume":"8","author":"Shao","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.exer.2018.11.022_bib56","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.exer.2006.07.007","article-title":"Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization","author":"Shi","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.11.022_bib57","article-title":"Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage","volume":"9","author":"Silva","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.exer.2018.11.022_bib58","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/archophthalmol.2012.1611","article-title":"Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1","author":"Sohn","year":"2012","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2018.11.022_bib59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1011947301849","article-title":"Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells","author":"Tsou","year":"2001","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.exer.2018.11.022_bib60","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1124\/mol.105.020941","article-title":"Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist","author":"Umeda","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.exer.2018.11.022_bib61","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1749-6632.2001.tb03526.x","article-title":"Role of fibrin matrix in angiogenesis","volume":"936","author":"van Hinsbergh","year":"2001","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.exer.2018.11.022_bib62","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1021\/acs.molpharmaceut.6b00056","article-title":"Joint antiangiogenic effect of ATN-161 and anti-VEGF antibody in a rat model of early wet age-related macular degeneration","volume":"13","author":"Wang","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.exer.2018.11.022_bib4a","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0014-4835(05)80001-6","article-title":"Monoclonal antibodies against CD54 (ICAM-1) and CD11a (LFA-1) prevent and inhibit endotoxin-induced uveitis","volume":"60","author":"Whitcup","year":"1995","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2018.11.022_bib63","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1167\/iovs.05-1314","article-title":"SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity","author":"Wilkinson-Berka","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.11.022_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028933","article-title":"Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344","volume":"6","author":"Xie","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.exer.2018.11.022_bib65","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000345070","article-title":"Targeting of integrin-linked kinase with small interfering RNA inhibits VEGF-induced angiogenesis in retinal endothelial cells","volume":"49","author":"Xie","year":"2013","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.exer.2018.11.022_bib67","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1076\/ceyr.28.5.359.28678","article-title":"Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist","author":"Yasukawa","year":"2004","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2018.11.022_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.347","article-title":"Angiopoietin 2 induces astrocyte apoptosis via alphavbeta5-integrin signaling in diabetic retinopathy","author":"Yun","year":"2016","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.exer.2018.11.022_bib69","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1167\/iovs.09-3575","article-title":"Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment","author":"Zahn","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2018.11.022_bib70","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archophthalmol.2009.265","article-title":"Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization","author":"Zahn","year":"2009","journal-title":"Arch. Ophthalmol."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483518305220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483518305220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T17:43:51Z","timestamp":1572975831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483518305220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":72,"alternative-id":["S0014483518305220"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2018.11.022","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2018.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}